Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11999123 | 0.83 | PDE2A (0.58) | PDE2ACES2MEN1KMT2APTPN5 | |
| SCHEMBL1538943 | 0.82 | PDE2A (0.56) | PDE2ACES2PTPN5KIF11TSHR | |
| SCHEMBL21180443 | 0.80 | PDE2A (0.57) | PDE2ACES2MEN1KMT2APTPN5 | |
| SCHEMBL21994511 | 0.77 | PDE2A (0.51) | PDE2ACES2PTPN5KIF11TSHR | |
| SCHEMBL22140215 | 0.76 | PDE2A (0.51) | PDE2ACES2MEN1KMT2AKIF11 | |
| SCHEMBL17972841 | 0.76 | CASR (0.41) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31409998 | 0.75 | HDAC6 (0.38) | PDE2ATSHRMAPK1 | |
| SCHEMBL963755 | 0.74 | PDE2A (0.58) | PDE2ACES2KIF11TSHR | |
| SCHEMBL12773796 | 0.74 | PDE2A (0.49) | PDE2ACES2MEN1KMT2AKIF11 | |
| SCHEMBL27537004 | 0.73 | ESR1 (0.52) | PDE2ACES2KIF11TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PDE2A 1/4885CES2 249/4885MEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.